Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Acute StrokeIschemic Stroke, AcuteCerebral Infarction
Interventions
DRUG

Tirofiban Hydrochloride

Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.

DRUG

Standard medical treatment (SMT)

Patients will receive standard antiplatelet therapy.

Trial Locations (1)

100053

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Capital Medical University

OTHER